XLO

7.4301.07%
RR

Rene Russo

President, CEO & Director

Dr. Rene Russo, BCPS, PharmD., is Scientific Advisor of Pylum Biosciences, Inc. Dr. Russo serves as Director at Celsius Therapeutics, Inc. since May 2020. Since May 2019, Dr. Russo has been the Chief Executive Officer and Director of Xilio Therapeutics, Inc., (formerly Akrevia Therapeutics) and serves as its President since September 2023 and served as its President since May 2021 until June 2022. Dr. Russo served as entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, from November 2018 to May 2019. Dr. Russo was a Representative at Cubist Pharmaceuticals Inc. Dr. Russo served as Vice-President of Global Medical Affairs at Cubist Pharmaceuticals Inc. She Co-Founded Adagio Therapeutics, Inc. and had been its Independent Chair of the Board since July 2020 until June 2022. She serves as Observer and Member of Scientific Advisory Board at AvidBiotics Corp. Prior to Arsanis, Dr. Russo served in various roles over 11-year period at Cubist Pharmaceuticals (Cubist), focused on the development and commercialization of infectious disease therapeutics, from 2003 until its acquisition by Merck in May 2015. As Vice President of an 80+ person global team, Dr. Russo oversaw the clinical microbiology program (including extensive in vitro and animal work to support dose selection and PK/PD analyses), contributed to the design of multiple Phase 1 to Phase 3 clinical studies and directly managed the oversight of several global burden of disease programs, including urosepsis and nosocomial pneumonia, to understand the outcomes and unmet medical needs in these infectious diseases. In her role at Cubist, she was also responsible for the oversight of more than 140 studies designed to further understand Gram-positive and Gram-negative infections, including epidemiology, resistance patterns and the study of various treatments (including combination therapies) across nonclinical and clinical studies. Dr. Russo directly oversaw investigator-initiated research for a broad portfolio of anti-infectives, including daptomycin, fidaxomicin, ceftolozane/tazobactam and tedizolid. From 1999 to 2004, Dr. Russo held roles of increasing responsibility at Bristol-Myers Squibb where she started her industry career as a Postdoctoral Fellow in Industrial Pharmacy Infectious Diseases. Dr. Russo also serves as a director of Life Science Cares. She also held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital before joining the biotechnology industry. She also serves as Atlas Advisor at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since December 2024. She has expertise as an executive at public and private pharmaceutical companies and has expertise in clinical development and commercialization of therapeutics targeting infectious diseases Dr. Russo received her Pharm. D. and Bachelor of Science in Pharmacy from Rutgers University and holds a Board of Pharmacy Specialties Pharmacotherapy Certification (BCPS). D, BCPS. She served as Director at X4 Pharmaceuticals, Inc. (formerly, Arsanis, Inc.) since March 13, 2019 until November 2021. and Arsanis from April 2016 o March 2019. Dr. Russo served as Chief Executive Officer and President at Arsanis, Inc. from April 2016 to November 26, 2018. Dr. Russo served as Chief Development Officer of Arsanis Biosciences from July 2015 to May 9, 2016 and Arsanis, Inc. from July 2015 until April 2016. She completed a post- doctoral fellowship in infectious diseases with Bristol-Myers Squibb Company.

Positions